🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
46

Quick answer

Novartis India has 46 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 68Ga-NNS309

    Novartis Pharmaceuticals

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  2. A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  3. A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease

    Novartis Pharmaceuticals

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  4. A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations

    Novartis Pharmaceuticals

    Advanced malignancies that harbor IDH1R132 mutations

    phase 1 other active

    1 trial

  5. A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants

    Novartis Pharmaceuticals

    Healthy volunteers

    phase 1 other active

    1 trial

  6. A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  7. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  8. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  9. A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  10. A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part

    Novartis Pharmaceuticals

    Heart failure (HF)

    phase 1 other active

    1 trial

  11. A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors

    Novartis Pharmaceuticals

    Advanced solid tumors

    phase 1 other active

    1 trial

  12. A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  13. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  14. A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  15. A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  16. A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid arthritis (RA)

    Novartis Pharmaceuticals

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  17. A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participants with systemic lupus erythematosus (SLE)

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  18. A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  19. A study of safety and efficacy of novel targeted therapy combinations in adult patients with advanced or metastatic colorectal cancer.

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  20. DABRAFENIB MESYLATE, TMT212, CANAKINUMAB, DKY709, LXH254, TRAMETINIB DIMETHYL SULFOXIDE, NIR178, MCS110, LXH254, INC280, TMT212, PDR001, NIR178, PDR001, NIZ985, TRAMETINIB DIMETHYL SULFOXIDE, LAG525, NIR178, LXH254, DABRAFENIB MESYLATE

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  21. INC280 single agent

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  22. Imatinib/Acetaminophen

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia (CML)

    phase 1 small molecule completed

    1 trial

  23. Indacaterol (QAB149)

    Novartis Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  24. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  25. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  26. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  27. LDT600 (Telbivudine)

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  28. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  29. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  30. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  31. Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  32. MBG453

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  33. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  34. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  35. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  36. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  37. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  38. Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  39. QEQ278

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 mab terminated

    1 trial

  40. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  41. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  42. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  43. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  44. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  45. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  46. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

46 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.